Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Alveolar nitric oxide and asthma control in mild untreated asthma

Test for Respiratory and Asthma Control in Kids (TRACK): Clinically meaningful changes in score Robert S. Zeiger, MD, PhD, Michael Mellon, MD, Bradley.

Risk of an asthma exacerbation after bariatric surgery in adults

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Michael E. Wechsler, MD, Michel Laviolette, MD, Adalberto S

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Badrul A. Chowdhury, MD, PhD

Perimenstrual increase in bronchial hyperreactivity in premenopausal women: Results from the population-based SAPALDIA 2 cohort Julia Dratva, MD, MPH,

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Test for Respiratory and Asthma Control in Kids (TRACK): A caregiver-completed questionnaire for preschool-aged children Kevin R. Murphy, MD, Robert.

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Physician needs in health informatics: Just ask the docs

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature Jessica P. Rajan, MD, Nathan E. Wineinger,

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Prognostic value of cluster analysis of severe asthma phenotypes

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Roles of arginase variants, atopy, and ozone in childhood asthma

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Early decreases in blood eosinophil levels with reslizumab

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

News Beyond Our Pages Journal of Allergy and Clinical Immunology

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

What is an “eosinophilic phenotype” of asthma?

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Autophagy: Nobel Prize 2016 and allergy and asthma research

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Higher incidence of pediatric anaphylaxis in northern areas of the United States William J. Sheehan, MD, Dionne Graham, PhD, Lin Ma, MS, Sachin Baxi,

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

High prevalence of severe asthma in a large random population study

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia.

Paul V. Licciardi, PhD, Anne Balloch, MSc, Fiona M

Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations Eric D. Bateman, MD, Roland Buhl, MD, Paul.

Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe.

News Beyond Our Pages Journal of Allergy and Clinical Immunology

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,

Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab Aidan Long, MD, Abdelkader Rahmaoui, MD, Kenneth.

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

News Beyond Our Pages Journal of Allergy and Clinical Immunology

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies Frank C. Albers, MD, PhD, Robert G. Price,

Presentation transcript:

Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M. Griffin, PhD, Bongin Yoo, PhD, Ahmar Iqbal, MB BS, MBA, Thomas B. Casale, MD Journal of Allergy and Clinical Immunology Volume 143, Issue 4, Pages 1629-1633.e2 (April 2019) DOI: 10.1016/j.jaci.2018.11.032 Copyright © 2018 The Authors Terms and Conditions

Fig 1 A, Mean exacerbation at baseline and week 48. B, Mean change (gray bar) in ACT score from baseline (white bar) at week 48 of omalizumab treatment in ACO and asthma cohorts. Journal of Allergy and Clinical Immunology 2019 143, 1629-1633.e2DOI: (10.1016/j.jaci.2018.11.032) Copyright © 2018 The Authors Terms and Conditions

Fig E1 Patient population identification. FVC, Forced vital capacity. Journal of Allergy and Clinical Immunology 2019 143, 1629-1633.e2DOI: (10.1016/j.jaci.2018.11.032) Copyright © 2018 The Authors Terms and Conditions

Fig E2 Mean (95% CI) change from baseline in postbronchodilator FEV1 after 12 months of omalizumab in the ACO and non-ACO cohorts. Journal of Allergy and Clinical Immunology 2019 143, 1629-1633.e2DOI: (10.1016/j.jaci.2018.11.032) Copyright © 2018 The Authors Terms and Conditions